[1] Belenguer G, Mastrogiovanni G, Pacini C, et al. RNF43/ZNRF3 loss predisposes to hepatocellular-carcinoma by impairing liver regeneration and altering the liver lipid metabolic ground-state. Nat Commun,2022,13(1):334. [2] He DD, Shang XY, WangN,et al. BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage. Oncogene,2022,41(10):1397-1409. [3] Lee GW,Hur W, Kim JH,et al. Nardostachys jatamansi root extract attenuates tumor progression in hepatocellular carcinoma via inhibition of ERK/STAT3 pathways. Anticancer Res,2021,41(4):1883-1893. [4] Rupprechter SAE, Sloan DJ, Oosthuyzen W,et al. MicroRNA-122 and cytokeratin-18 have potential as a biomarkers of drug-induced liver injury in European and African patients on treatment for mycobacterial infection. Br J Clin Pharmacol,2021,87(8):3206-3217. [5] Zhou S, Ma Y, LiuX,et al. Targeted delivery of glypican 3 (GPC3) antibody-modified microRNA (miR let-7b-5p) polymer nanoparticles to sorafenib-resistant hepatsocellular carcinoma cells. J Biomed Nanotechnol,2021,17(4):677-690. [6] Li D, Li N, ZhangYF,et al. Persistent polyfunctional chimeric antigen receptor T Cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice. Gastroenterology,2020,158(8):2250-2265. [7] 中国抗癌协会肝癌专业委员会. 原发性肝癌规范化病理诊断指南(2015年版) . 中华肝胆外科杂志,2015,7 (21): 151. [8] Li X, Ye Z, LinS,et al. Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram. BMC Cancer,2021,21(1):701. [9] 李欢,李扬,杜娟,等.肝细胞癌组织Glypican3和Sonic Hedgehog蛋白表达及其功能分析.实用肝脏病杂志,2022,25(1):83-87. [10] Sejben A, Voros A, Golan A,et al. The added value of SOX10 immunohistochemistry to other breast markers in identifying cytokeratin 5-positive triple negative breast cancers as of mammary origin. Pathobiology,2021,88(3):228-233. [11] 刘洁,周晟.联合检测CK5/6、CK7和TTF-1在腹壁肿块转移癌来源鉴别中的作用.临床与实验病理学杂志,2020,36(11):1328-1329. [12] Fabian A,Stegner S, Miarka L,et al. Metastasis of pancreatic cancer: An uninflamed liver micromilieu controls cell growth and cancer stem cell properties by oxidative phosphorylation in pancreatic ductal epithelial cells. Cancer Lett,2019,45(3):95-106. [13] Benabou E, Salame Z, Wendum D,et al. Insulin receptor isoform a favors tumor progression in human hepatocellular carcinoma by increasing stem/progenitor cell features. Cancer Lett,2019,45(10):155-168. [14] Yamashiki N, Haga H, Ueda Y,et al. Use of nakanuma staging and cytokeratin 7 staining for diagnosing recurrent primary biliary cholangitis after living-donor liver transplantation. Hepatol Res,2020,50(4):478-487. [15] 罗教秀,储兵,陈杰伟,等.免疫组织化学双重染色检测肺组织p63、ck7表达在非小细胞肺癌临床诊断和转移中的应用.临床与病理杂志,2023,43(1):9-15. [16] Rodakowska E, Walczak-Drzewiecka A, Borowiec M,et al. Recombinant immunotoxin targeting GPC3 is cytotoxic to H446 small cell lung cancer cells. Oncol Lett,2021,21(3):222. [17] Schepers EJ, Lake C, Glaser K,et al. Inhibition of glypican-3 cleavage results in reduced cell proliferation in a liver cancer cell line. J Surg Res,2023,28(2):118-128. [18] Du K, Li Y, LiuJ,et al. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC. Mol Ther,2021,29(4):1572-1584. [19] Pei M, Li H, ZhuY,et al. In vitroevidence of oncofetal antigen and TLR-9 agonist co-delivery by alginate nanovaccines for liver cancer immunotherapy. Biomater Sci,2022,10(11):2865-2876. [20] 李程,张惠文,容鹏飞. 靶向磷脂酰肌醇蛋白聚糖-3治疗肝细胞癌的临床应用前景.中国生物化学与分子生物学报,2021,37(2):153-160. |